Predictive’s mission is to revolutionize the care of patients through novel gene-based diagnostics and companion therapeutics. Our relentless questioning and persistence will assist in our endeavors to eliminate diseases in our generation and generations to come.
Predictive Technology Group, Inc. (PRED) through its wholly owned subsidiary Predictive Therapeutics, Inc. revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression. PRED uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.